Adjuvant treatment and results;Tratamiento adyuvante y resultados

Cirugia Espanola

Volumn 73, Issue 1, 2003, Pages 38-45

  Grávalos Castro, Cristina ^a   Ángeles Pérez Escutia, M A ^b  

^a Servicio de Oncología Médica Hospital Universitario de Torrejón   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Adjuvant; Chemotherapy; Colon cancer; Elderly; Immunotherapy; Neoadjuvant; Radiotherapy; Randomized trials; Rectal cancer

Indexed keywords

EID: 84897776291     PISSN: 0009739X     EISSN: 1578147X     Source Type: Journal    
DOI: 10.1016/S0009-739X(03)72089-2     Document Type: Article

References (51)

1. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 5th ed. Philadelphia Lippincott-Raven Publishers, 1997.
2. Gunderson L.L., Sosin H. Areas of failure found at reoperation (second or symptomatic look) following " curative surgery" for adenocarcinoma of the rectum: clinicopathologic correlation and implications for adjuvant therapy. Cancer 1974, 34:1278-1292.
3. Cohen A, Minsky B, Schilsky. Cancer of the colon. En: Vita V, Hellman S, Rosenberg S, editors. Cancer: principlespractice of oncology. 5th ed. 1997; p. 1144-97.
4. Grage T.B., Moss S.E. Adjuvant chemotherapy in cancer of the colon and rectum: demostration of effectiveness of prolonged 5-FU chemotherapy in a prospectively controlled randomized trial. Surg Clin North Am 1981, 61:1321-1329.
5. Higgins G.A., Lee L.E., Dwight R.W. The case for adjuvant 5-fluorouracil in colorectal cancer. Cancer Clin Trials 1978, 1:35.
6. Boice J.D., Greene M.H., Killen J.Y., Ellenberg S.S., Keehn R.J., McFadden E., et al. Leukemia and pre-leukemia after adjuvant treatment of gastrointestinal cancer wiht semustine (methyl-CCNU). N Engl J Med 1983, 309:1079-1084.
7. Buyse M., Zeleniuch-Jacquotte A., Chalmers T.C. Adjuvant therapy of colorectal cancer: why we still don't know. JAMA 1998, 259:3571-3578.
8. Laurie J.A., Moertel C.G., Fleming T.R., Wieand H.S., Leigh J.E., Rubin J., et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. J Clin Oncol 1989, 7:1447-1456.
9. Moertel C.G., Fleming T.R., Macdonald J.S., Haller D.G., Laurie J.A., Goodman P.J., et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990, 322:352-358.
10. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990, 264:1444-1450.
11. Taal B.G., Van Tinteren H., Zoetmulder F.A. Adjuvant 5-FU plus levamisol in colonic or rectal cancer: improved survival in stage II and III. Br J Cancer 2001, 85:1437-1443.
12. Advanced Colorectal Cancer Meta-Analysis Projet. Modulation of fluorouracil by leucovorin in patients with advanced colorectal evidence in terms of response rate. J Clin Oncol 1992, 10:896-903.
13. O'Connell M., Mailliard J., Kahn M., Macdonald J.S., Haller D.G., Mayer R.J., et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997, 15:246-250.
14. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995, 345:939-944.
15. Wolmark N., Rockette H., Fisher B., Wickerham D.L., Redmond C., Fisher E.R., et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993, 11:1879-1887.
16. Haller D., Catalano P.J., Macdonald J.S., Mayer R.J. Fluorouracil, leucovorin and levamisole adjuvant therapy for colon cancer. Five year final report of INT-0089. Proc Am Soc Clinic Oncol 1998, 17:256a. [abstract 982].
17. O'Connell M., Laurie J.A., Kahn M., Fitzgibbons R.J., Erlichman C., Sheperd L., et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998, 16:295-330.
18. Wolmark N., Rockette H., Mamounas E., Jones J., Wieand S., Wickerham D.L., et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluororuracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: Results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999, 17:3553-3559.
19. Bleeker W.A., Mulder N.H., Hermans J., Otter R., Plukker J.T. The addition of low-dose leucovorin to the combination of 5-fluorouracil-levamisole does not improve survival in the adjuvant treatment of Dukes' C colon cancer. IKN Colon Trial Group. Ann Oncol 2000, 11:547-552.
20. Porschen R., Bermann A., Loffler T., Haack G., Rettig K., Anger Y., et al. Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01. J Clin Oncol 2001, 19:1787-1794.
21. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial-QUASAR Collaborative Group. Lancet 2000, 355:1588-1596.
22. Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of 5-fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998, 16:301-308.
23. Saini A., Cunningham D., Norman A., Hill M.E., Tait D., Hickish T., et al. Multicentre randomized trial of protracted venous infusion (PVI) 5- FU compared to 5-FU/folinic acid (5-FU/FA) as adjuvant therapy for colorectal cancer. Proc Am Soc Clin Oncol 2000, 19:240a. [abstract 928].
24. Poplin E., Benedetti J., Estes N., Haller D., Mayer S., Goldberg R., et al. Phase III randomized trial of bolus 5-FU/leucovorin/levamisol versus 5-FU continuous infusion/levamisole as adjuvant therapy for high risk colon cancer (SWOG 9415/INT-0153. Proc Am Soc Clin Oncol 2000, 19:240a. [abstract 931].
25. Andre T., Colin P., Louvet E., Gamelin E., Bouche O., Achille E., et al. Phase III trial (GERCOR C96.1) comparing bimonthly LV5-FU2 to monthly 5-FU-leucovorin hgi dose (LV hd) in patients with Dukes B2 and C colon cancer. Proc Am Soc Clin Oncol 2002, 21:133a. [abstract 529].
26. Van Custem E, Twelves C., Cassidy J., Allman D., Bajetta E., Boyer M., et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001, 19:4097-4106.
27. Pazdur R., Douillard J.Y., Skillings J.R., Eisenberg P.D., Davidson N., Harper P., et al. Multicentre phase III study of UFT in combination with leucovorin in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999, 18:263a. [abstract 1009].
28. Maughan T.S., James R.D., Kerr D.J., Ledermann J.A., McArdle C., Seymour M.T., et a.l. for the British MRC Colorectal Cancer Working Party. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet 2002, 359:1555-1563.
29. Douillard J.Y., Cunningham D., Roth A.D., Navarro M., James R.D., Karasek P., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355:1041-1047.
30. De Gramont A, Figer A., Seymour M., Homerin M., Hmissi A., Cassidy J., et al. Leuvovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 8:2938-2947.
31. Chau I., Cunningham D. Adjuvant chemotherapy in colon cancer: state of the art. Educational Book Am Soc Clin Oncol 2002, 21:228-239.
32. Mamounas E., Wieand S., Wolmark N., Bear H.D., Atkins J.N., Jones J., et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvants studies (C-01, C-02, C-03, and C-04. J Clin Oncol 1999, 17:1349-1355.
33. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 1999, 17:1356-1363.
34. Scheele J., Stangl R., Altendorf-Hofmann A., Paul M. Resection of colorectal liver metastases. World J Surg 1995, 19:59-71.
35. Smith J.W., Fortner J.G., Burt M. Resection of hepatic and pulmonary metastases from colorectal cancer. Surg Oncol 1992, 1:399-404.
36. Iwatsuki S., Shan B.W., Starzl T.E. Experience with 150 liver resections. Ann Surg 1983, 197:247-253.
37. Kemeny N., Huang Y., Cohen A.M., Shi W., Conti J.A., Brennan M.F., et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999, 341:2039-2048.
38. Kemeny M.M., Adak S., Gray B., Macdonald J.S., Smith T., Lipsitz S., et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy -an intergroup study. J Clin Oncol 2002, 20:1499-1505.
39. Giacchetti S., Itzhaki M., Gruia G., Adam R., Zidani R., Kunstlinger F., et al. Long-term survival of patients with irresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999, 10:663-669.
40. Bismuth H., Adam R., Levi F., Farabos C., Waechter F., Castaing D., et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996, 224:509-522.
41. Hutchins L.F., Unger J.M., Crowley J.J., Coltman C.A., Albain K.S. Underrepresentation of patients 65 years of age or older in cancertreatment trials. N Engl J Med 1999, 341:2061-2067.
42. Sargent D.J., Goldberg R.M., Jacobson S.D., Macdonald J.S., Labianca R., Haller D.G., et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001, 345:1091-1097.
43. Liver Infusion Meta-analysis Group. Portal Vein Chemotherapy for Colorectal Cancer: a meta-analysis of 4.000 patients in 10 Studies. J Nat Cancer Inst 1997, 89:497-505.
44. Hoover H.C., Brandhorst J.S., Peters L.C., Surdyke M.G., Takeshita Y., Madariaga J., et al. Adjuvant active specific immunotherapy for human colorectal cancer: 6,5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 1993, 11:390-399.
45. Vermorken J.B., Caessen A.M., Van Tintern H., Gall H.E., Ezinga R., Meijer S., et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 1999, 353:345-350.
46. Harris J., Ryan L., Adams G., Benson A., Haller A. Survival and relapse in adjuvant autologous tumor vaccine therapy for Dukes' B and C colon cancer. Est 5283. Proc Am Soc Clin Oncol 1994, 13:294. [abstract 955].
47. Riethmueller G., Holz E., Schlimok G., Schimiegel W., Raab R., Höffken K., et al. Monoclonal antibody therapy for resected Dukes C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998, 16:1788-1794.
48. Punt C.J., Nagy A., Douillard J.Y., Figer A., Skovsgaard T., Monson J., et al. Edrecolomab (17-1A antibody) alone or in combination with 5- fluoruracil based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a phase III study. Proc Am Soc Clin Oncol 2001, 20:123a. [abstract 487].
49. Fields A.L., Keller A.M., Schwartzberg L., Bernard S., Pazdur R., Kardinal C., et al. Edrecolomab (17-1A antibody) (EDR) in combination with 5-fluorouracil (FU) based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a randomised north american phase III study. Proc Am Soc Clin Oncol 2002, 21:128a. [abstract 508].
50. Minsky B. Adjuvant therapy for rectal cancer. Educational Book. Am Soc Clinic Oncology 2002, 50:472-477.
51. Hyams D.M., Mamounas E.P., Petrelli N., Rockette H., Jones J., Wieand S., et al. A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum. Dis Colon Rectum 1997, 2:131-139.